Lincoln Nadauld, MD, PhD, executive director of Intermountain Healthcare’s Precision Genomics Program, has been honored with the prestigious Cancer Community (C2) award for advancing precision medicine to bring more personalized treatments to cancer patients.

During a virtual announcement, presenters pointed to Dr. Nadauld’s groundbreaking work at Intermountain’s Precision Genomics program for increasing life expectancy of cancer patients while lowering their total cost of care.

The national C2 Awards are presented annually by biopharmaceutical company AstraZeneca in partnership with Scientific American Custom Media—to honor unsung heroes of cancer care. The awards are part of the broader YOUR Cancer Program which was launched to spotlight those contributing toward eliminating cancer as a cause of death. This year there were more than 130 nominations from 31 states. The C2 Awards feature four categories: extending quality care to underserved communities, improving the patient experience, advancing precision medicine, and doing something tangible and inspiring for patients.

As the winner of a C2 Award, Dr. Nadauld receives $50,000 to donate to a non-profit of his choice. He plans to give the money to Intermountain Precision Genomics to continue benefiting patients and research in the fight against cancer.